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Objectives: Chronic hepatitis C virus (HCV) is a leading cause of hospitalization and death 
in populations coinfected with human immunodeficiency virus (HIV). Sofosbuvir (SOF) is a 
pan-genotypic drug that should be combined with other agents as an oral treatment for HCV. We 
performed a 5-year horizon budget impact analysis of SOF-based regimens for the management 
of HIV/HCV-coinfected patients.
Methods: A multicenter, prospective evaluation was conducted, involving four Italian Infectious 
Diseases Departments (Galliera, San Martino, Sanremo, and La Spezia). All 1,005 genotype-
coinfected patients (30% cirrhotics) under observation were considered (patients in all disease-
stages were considered: chronic hepatitis C, cirrhosis, transplant, hepatocellular carcinoma). 
Disease stage costs per patient were collected; the expected disease progression in the absence 
of treatment and sustained virological response (SVR) success rate for SOF-based regimens 
were calculated based on the literature and expert opinion. Drug prices were based on what the 
National Health Service paid for them. The comparison of “no treatment” disease progression 
costs versus the economic impact of SOF-based regimens was investigated.
Results: Over the following 5 years, the disease progression scenario resulted in direct costs of 
approximately €54 million. Assuming an SVR success rate of 90%, average SOF-based regimens 
cost up to €50,000 per person, resulting in a final cost of more than €56 million, so this option 
is not economically viable. At the average price of €12,000, SOF-based regimens, expense was 
€17 million, saving 68%. At this price level, the economic resources invested in treating mild to 
moderate fibrosis stage patients would be equal to the amount of direct costs of disease manage-
ment in this stage, resulting in a valid return of investment in the short-term.
Conclusion: Given the high rates of SVR, in the Italian Healthcare System, SOF-based 
regimens, price is a determinant and a predictor of the overall cost for the Hepatitis C patient’s 
management. At the average price per therapy of €12,000 over the next 5 years, SOF-based 
regimens are becoming highly sustainable.
Keywords: HCV treatment, sofosbuvir, HIV, budget impact, HIV/HCV coinfection, 
cirrhosis
Introduction
Human immunodeficiency virus (HIV) and hepatitis C virus share the same mode of 
transmission (through direct blood to blood contact), and therefore, the incidence of 
coinfection in Italy is extremely high, reaching a peak of 45% as reported by Italian 
Cohort Naive Antiretrovirals foundation in 2002.1 This issue is largely due to the high 
percentage of former drug users among Italian people living with HIV.1
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Table 1 hiV/hCV-coinfected patients* under observation in 
four ligurian hospitals (galliera, san Martino, sanremo, and la 
spezia, as of May 2015)
Fibrosis stage N
Chronic hepatitis C (ChC) F0–F2 528
F3 174
liver cirrhosis F4 288
hCC  15
Total 1,005
Note: *nine patients underwent liver transplantation.
Abbreviations: hCC, hepatocellular carcinoma; hCV, hepatitis C virus; hiV, 
human immunodeficiency virus.





The most recent guidelines from the European Liver Asso-
ciation do not make any distinction between mono or coinfected 
patients2 for the treatment with anti-HCV directly active anti-
virals. On the other hand, it is generally accepted that in HIV/
HCV patients there is faster progression toward cirrhosis and 
hepatocellular carcinoma (HCC) than in mono-infected.3–11
Several study cohorts have shown the natural history of 
end-stage liver disease in HIV/HCV-coinfected patients.12–14 
In addition, the natural history of compensated cirrhosis in 
coinfected patients has been described in smaller cohorts of 
less than 200 patients.15,16 Moreover in HIV/HCV coinfection, 
SVR may also decrease the progression of HIV infection and 
mortality not related to liver disease.17,18
The clinical benefits associated with the eradication of 
HCV have been well characterized in patients with advanced 
fibrosis or cirrhosis but not in patients with less advanced 
stages of liver fibrosis. Also, a comprehensive costs–oppor-
tunity evaluation in patients with a less severe disease is 
missing. This is a relevant question, particularly in HIV/HCV-
coinfected patients, for whom the delivery of effective HCV 
treatment could be a priority even in mild to moderate stages 
of liver fibrosis, in order to prevent a more rapid disease 
progression. Based on hospital databases, in Liguria region 
one out of three HIV patients is coinfected with HCV; in 
addition, Liguria has the highest prevalence of AIDS among 
other regions in Italy.19 Chronic HCV in Italy is also a leading 
cause of infectious admissions in hospital for HIV patients.20 
Therefore, earlier treatment in this population is crucial in 
terms of clinical benefits, prevention of disease progression 
and HCV-related health care direct costs limitation.21 Sofos-
buvir (SOF) is a pan-genotypic drug which can be combined 
with other agents like ribavirin, simeprevir, daclatasvir or, 
in single-tablet regimen, together with ledipasvir as all oral 
treatment for HCV, with different entry price levels paid and 
reimbursed by the National Health Service.
Also, SOF and sofosbuvir/ledipasvir are linked to a price/
volume payback scheme covered by a secrecy agreement22 
that, in practice, affects regimen’s cost variations. Due to 
budget constraints, as of year 2015, the national registra-
tion in terms of reimbursement of such regimens has been 
restricted to patients with more severe stages of disease, 
according to ethical and clinical considerations.23–26 But, we 
may expect in the near future costs declining, according to 
new price negotiations that try to include patients with less 
severe conditions to be eligible to reimbursement by National 
Health Authorities.
Therefore, we tried to assess a 5-year horizon budget 
impact (ie, the Regional Health System Management’s 
term) and cost saving analysis related to the effects of SVR 
after treatment with SOF regimens on mortality and liver 




A Markov model has been applied to conduct a multicenter, 
5-year horizon prospective costs evaluation, involving four 
Italian Infectious Diseases Departments (Galliera, San 
Martino, Sanremo, and La Spezia) in Liguria region, Italy. 
In all, 1,005 all genotypes adult HIV/HCV patients, under 
observation by clinicians as of May 2015, were included in the 
analysis. The patients’ characteristics in the group of pooled 
data were classified according to their current disease stage: 
non cirrhotics, cirrhotics, HCC, and transplants (Table 1).
On completion of treatment (at 12 or 24 weeks), patients 
who achieve SVR are considered to be permanently cured of 
the infection (SVR at 12 weeks has been set as an appropriate 
endpoint for regulatory approval and is accepted by most clini-
cal and regulatory authorities).27 Patients who do not achieve 
SVR progress to more advanced stages of the disease. In this 
case, transition probabilities and disease progression rates are 
based both on literature and clinical experts’ opinion. All cause 
mortality rates were applied to all health states in the model.
The cycle length was 3 months to account for the 12-week 
treatment duration for some SOF-based regimens, costs and 
outcomes were discounted at 3% as recommended by the 
Italian Association of Health Economics.28 All data were 
anonymously processed and analyzed. The comparison of 
1) “no treatment” disease progression costs vs 2) the eco-
nomic impact of SOF-based regimens was investigated.
This study was developed with the data available inside 
the IANUA study (Indagine  sull’appropiatezza prescrittiva 
degli antiretrovirali  antiretrovirali ) which was approved by 
Comitato Etico Regione Liguria, with  provision number PR 
032 REG2014,  obtained on 08 April, 2014.
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Table 2 Transition probabilities: expected progression rates in 5 years (without treatment intervention)
Year 0 Year 5 Probabilities Source
non-cirrhotic, hiV-coinfected Base case: 0 Benhamou et al7
Compensated cirrhosis 5 years: 0.05
Decompensated cirrhosis 5 years: 0.06
hCC 5 years: 0.06
liver transplant 5 years: 0.04
Death 5 years: 0.06
Compensated cirrhosis Base case: 0
Decompensated cirrhosis 5 years: 0.15 Fattovich et al8
hCC 5 years: 0.12
liver transplant 5 years: 0.12 Fattovich et al9
Death 5 years: 0.10
Decompensated cirrhosis Base case: 0 Pineda et al12
hCC 5 years: 0.12
liver transplant 5 years: 0.12
Death 5 years: 0.10
hCC Base case: 0
Death 5 years: 0.4
liver transplant 5 years: 0.5 Expert opinion
Pre-OlT/Post-OlT Base case: 0
Death, Year 3 5 years: 0.5 Clinical observation
Note: The probabilities show the probability for each single patient to progress from the conditions shown in Year 0 to each single condition by 5 year. 
Abbreviations: OLT, liver transplant; HCC, hepatocellular carcinoma; HIV, human immunodeficiency virus.




sOF-based regimens for treatment of hiV/hCV-coinfected patients
Efficacy: SVR rates
The SVR rates of SOF-based regimens for each patient 
disease stage were derived from trials and literature29–33 and 
validated by expert opinion. The average SVR success rate 
for SOF-based regimens included in the model was 90%.
Transition probabilities
Transition probabilities in the analysis related to HCV pro-
gression from one disease stage to another were taken from 
the literature17,34–37 (Table 2); where this was not possible, we 
obtained them from expert opinion. These estimates were 
converted to annual probabilities for the analysis.
Resource consumption and costs
In this study, cost data were analyzed from the Regional 
Health Service point of view. Costs associated with each 
health state were obtained from the White Paper by the 
Italian Association of the Study of the Liver38 and the COME 
Study,21 which are aligned with the costs for each health 
state resulting from the Ospedale Galliera budgeting system 
(which is a component of Italian Network for Standard Costs 
in Healthcare). As part of the reimbursement agreement with 
the Italian reimbursement agency, we assumed that 24 weeks 
of treatment with SOF had the same price as 12 weeks of 
treatment. Drug prices (VAT included) for all the regimens 
used in the analysis are those applied to the Italian NHS 
hospital pharmacies (Table 3).
sensitivity analysis
The sensitivity analysis verified the impact of a series of vari-
ations of the base case with a large influence on the obtained 
results. A series of univariate analyses was carried out on 
some parameters of the simulation model, such as SVR rates, 
anti-HCV cost regime, and mortality rate. Each parameter was 
varied with ±10% with respect to the base-case scenario on 
the basis of Italian guidelines on economic evaluation.24
Results
Table 4 shows the main results. In the “disease progression” 
scenario, over the next 5 years, the disease progression with-
out treatments resulted in €54 million ca costs and 89 deaths. 
On the other hand, treatment containing SOF would save 68 
people from HCV-related deaths. Overall, the SOF-based 
regimens with an average price €50,000 do not offer a 
favorable cost saving profile, as this cost generates more than 
€56 million expense. Moreover, when the average price of 
an SOF regimen varies from €45,000 to €15,000 the budget 
impact ranges from €50 to €20 million ca, ie, saving from 6% 
to 53% of liver-related disease management costs, respec-
tively (min: 3.5€M–max: 34.1€ M ca). At the average price of 
€12,000, SOF-based regimens’ expense was €17 million ca, 
saving 68% (€37 million ca) of costs compared with the 
disease progression scenario.
This result indicates that at this price level, the economic 
resources invested to treat from mild to moderate fibrosis 





stage patients are equal to the amount of direct costs of 
disease management in this stage, resulting in a convenient 
return of investment in the short term. The sensitivity analysis 
carried out on the main variables does not highlight signifi-
cant variations with respect to the base case (Table 5).
Discussion
The use of SOF regimens substantially reduces the clinical 
burden of HCV disease. We decided to focus on SOF-based 
regimens because, today, it is the only pan-genotypic drug 
(backbone) available. Although several studies reported 
that SOF therapies are cost-effective,39–44 the resources 
needed to treat a large number of patients with HCV/HIV 
infection could be challenging for the Regional Healthcare 
System. On the other hand, an average SOF-based regimen 
price that starts descending progressively from the level 
of €45,000 would save direct costs optimizing economic 
resources and bringing a return on investments in the mid-
term, at the same time. SOF and sofosbuvir/ledipasvir joint 
reimbursed agreement is affected by a price/volume scheme 
leading to incremental economic payback when patient 
thresholds are achieved.45 In fact as stated in the National 
Drug Agency (AIFA) resolution published,46 Liguria region 
received its first amount of payback related to the usage 
of SOF-based regimens of €0.7 million starting to show 
benefit from the cost reduction. Therefore, it is reasonable 
to assume that in the near future the real average cost of 
SOF-based regimens will be lower than the initial entry 
prices. Finally, the agreement signed between the company 
and the AIFA lasts 18 months47,48 as a consequence it will 
expire by mid-2016 leading to a new price negotiation. 
To our knowledge, this is the first study that evaluates 
the budget impact of SOF-based regimens for HIV/HCV-
coinfected patients in Italy.
Our study presents some limitations. First, clinical 
disease progression and SVR rates included in our analy-
sis by clinicians may differ in clinical practice; therefore, 
our study used only the best available evidence on treat-
ment efficacy for this population. Moreover, this analysis 
assumed that the achievement of SVR was equivalent to a 
permanent cure of patients, which could overestimate the 
benefits of therapies. In addition, additional potential costs 
of failures related to adverse events and interactions were 
not calculated. We also did not include the future possibil-
ity of re-treatment with next generation of antiviral agents 
because of a lack of data at the time of this evaluation. 
A much more comprehensive evaluation may consider bud-
get impact including new unknown mono-infected patients 
that may emerge through awareness campaigns aiming to 
eradicate the disease. This data showing the reduction of 
coinfection of HIV/HCV is a clear sign that in a five year 
period the target population could not increase.49 Finally, 
this analysis was focused just on the HCV issues of such 
patients; additional HIV drugs expense and related direct 








Disease progression 9,347,851 8,433,814 3,364,394 33,260,750 54,406,809 89
 sOF-based regimen no 1 12,000 9,358,785 3,877,691 516,439 3,506,075 17,258,990 -37,147,819
 sOF-based regimen no 2 15,000 11,464,785 4,741,691 561,439 3,551,075 20,318,990 -34,087,819
 sOF-based regimen no 3 20,000 14,974,785 6,181,691 636,439 3,626,075 25,418,990 -28,987,819
 sOF-based regimen no 4 25,000 18,484,785 7,621,691 711,439 3,701,075 30,518,990 -23,887,819
 sOF-based regimen no 5 30,000 21,994,785 9,061,691 786,439 3,776,075 35,618,990 -18,787,819
 sOF-based regimen no 6 35,000 25,504,785 10,501,691 861,439 3,851,075 40,718,990 -13,687,819
 sOF-based regimen no 7 40,000 29,014,785 11,941,691 936,439 3,926,075 45,818,990 -8,587,819
 sOF-based regimen no 8 45,000 32,524,785 13,381,691 1,011,439 4,001,075 50,918,990 -3,487,819
 sOF-based regimen no 9 50,000 36,034,785 14,821,691 1,086,439 4,076,075 56,018,990 1,612,181
 sOF-based regimen no 10 55,000 39,544,785 16,261,691 1,161,439 4,151,075 61,118,990 6,712,181
Abbreviations: ChC, chronic hepatitis C; hCC, hepatocellular carcinoma; Diff, difference in cost; Dis Progr, disease progression; hCV, hepatitis C virus; hiV, human 
immunodeficiency virus; SOF, sofosbuvir.
Table 3 sOF-based regimens’ treatment prices (VaT included)
Treatment regimen Treatment prices (€) 
($12 weeks)
sOF + lDV (8 weeks) 29,810
sOF + lDV 44,770
sOF + sMV 57,200
sOF + DCV (60 mg/die) 59,400
sOF + DCV (90 mg/die) 78,100
Abbreviations: sOF, sofosbuvir; DCV, daclatasvir; lDV, ledispavir; sMV, simeprevir; 
mg/die, mg a day.































































































































































































































































































































































































































































































































































































































































































































































costs management were not considered but should be 
included by the Regional Healthcare System at the time of 
a comprehensive economic budget planning.
Conclusion
Given the high rates of SVR these results suggested that, in 
the Italian Healthcare System, SOF-based regimens’ price is 
a determinant and a predictor of the overall cost for the HCV 
management. At the average price per therapy of €12,000 over 
the next 5 years, SOF-based regimens are highly sustainable 
for the Healthcare System saving several million Euro of 
economic resource money needed to manage HCV in the 
HIV-coinfected population.
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